Commentary

Podcast

Unifying Industry to Better Understand GCP Guidance

Author(s):

Andy Studna, Senior Editor

In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.

David Nickerson, head of clinical quality management at EMD Serono, executive sponsor of TransCelerate's ICH E6(R3) Initiative & PhRMA topic lead on the ICH E6(R3) Expert Working Group; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, and ACRO member participating in the ICH E6(R3) Initiative with TransCelerate, discuss:

  • The newest ICH E6(R3) GCP guidelines
  • Industry collaboration through TransCelerate and ACRO's partnership
  • Tools to help stakeholders better understand the latest GCP guidelines
  • Their own recommendations for best practices in risk management and data governance
  • and more!

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
© JHVEPhoto - © JHVEPhoto - stock.adobe.com
August 1st 2025

FDA Crackdown on Trial Design: What July’s CRLs to Replimune and Capricor Mean for Sponsors

Andy Studna, Senior Editor
Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.
ACT Brief Episode 1: Placebos, Politics, and the Ethics of Vaccine Trials
August 1st 2025

ACT Brief Episode 1: Placebos, Politics, and the Ethics of Vaccine Trials

Applied Clinical Trials Editorial Staff
In this pilot episode of the Applied Clinical Trials Brief, we examine the renewed push for placebo-controlled vaccine trials in the US, why experts warn it violates core ethical standards, and how these proposals could jeopardize both participant safety and future innovation.
Report: Clinical Trial Searches Delay Treatment for Nearly 75% of Physicians
August 1st 2025

Report: Clinical Trial Searches Delay Treatment for Nearly 75% of Physicians

Don Tracy, Associate Editor
A new myTomorrows survey of physicians in the United States highlights the need for smarter, AI-driven tools to overcome inefficiencies in clinical trial access and improve patient care timelines.
Improving Relationships and Diversifying the Site Selection Process
August 1st 2025

Improving Relationships and Diversifying the Site Selection Process

Andy Studna, Senior Editor
In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Study: Social Media Outperforms Traditional Methods for Recruiting Patients with Depression in Clinical Trials
August 1st 2025

Study: Social Media Outperforms Traditional Methods for Recruiting Patients with Depression in Clinical Trials

Don Tracy, Associate Editor
Digital strategies such as video ads and pixel tracking helped researchers recruit faster, reach more diverse participants, and cut costs in a large-scale depression study.
ODAC Votes Against Risk-Benefit Profile of GSK’s Blenrep Combinations in Relapsed/Refractory Multiple Myeloma
August 1st 2025

ODAC Votes Against Risk-Benefit Profile of GSK’s Blenrep Combinations in Relapsed/Refractory Multiple Myeloma

Don Tracy, Associate Editor
Despite the setback with the Oncologic Drugs Advisory Committee vote, GSK emphasizes the unmet need in multiple myeloma and highlights global momentum behind Blenrep combination approvals.
© 2025 MJH Life Sciences

All rights reserved.